DUBLIN, Sept. 08, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/zdxh9r/investigation) has announced the addition of the "Investigation Report on China's Sevoflurane Market, 2010-2019" report to their offering.
Sevoflurane is an inhalational anaesthetic for maintenance of general anesthesia with the fastest onset and offset. And it not only has little influence on circulation, liver and kidney functions but also protects cardiac muscles. Therefore, sevoflurane has become the main inhaled anaesthetic which is especially fit for patients with myocardial damage. Anaesthetic is divided into local and general anaesthetic with the latter dominating the market.
In 1996, Ultane of Abbott entered China, followed by Sevorane of Maruishi and Sevoflurane of Baxter Healthcare Corporation. In 2007 and 2008 respectively, inhaled solution of sevoflurane made by Shanghai Hengrui Pharmaceutical and Lunan Better Pharmaceutical were approved by CFDA to enter the market too.
According to the Chinese government's statistics, the number of hospitalized cases rose from 115 million in 2008 to 192 million in 2013, among which a quarter need operations. And CAGR during this period exceeded 8%. Therefore it is clear to see that as operations rise in number, the demand for anaesthetics will rise too.
According to this market survey, the sales value of sevoflurane in sample hospitals rose from less than CNY 4 million in 2005 to over CNY 400 million in 2014 with CAGR during this period reaching 71%.
According to the market survey, Maruishi Pharmaceutical Co., Ltd.(JA), Shanghai Hengrui Pharmaceutical Co., Ltd, Baxter Healthcare Corporations (US), Jiangsu Hengrui Medicine Co., Ltd and Maruko(JA) occupy the market, among of which Maruishi Pharmaceutical Co., Ltd.(JA) had the largest market share of about 41% for sales value in 2014.
As the demand for anaesthetic keeps rising as a result of increasing operations, sevoflurane enjoys good market prospects.
Key Topics Covered:
1 Related Concepts of Sevoflurane
2 Market Profile of Sevoflurane in China
3 Survey on Sevoflurane Sales in China, 2010-2014
4 Survey on Market Share of Major Sevoflurane Manufacturers in China, 2010-2014
5 Survey on Dosage Forms of Sevoflurane in China, 2010-2014
6 Reference Price of Sevoflurane in Chinese Hospitals in 2014
7 Major Manufacturers of Sevoflurane in Chinese Market, 2010-2014
8 Market Outlook of Sevoflurane in China, 2015-2019
- Baxter Healthcare Corporation
- Jiangsu Hengrui Medicine Co., Ltd
- Lunan Better Pharmaceutical Co., Ltd
- Maruishi Pharmaceutical Co. Ltd.
- Shanghai Hengrui Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/zdxh9r/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets